Patients Selected for Definitive Concurrent Chemoradiation at High-volume Facilities Achieve Improved Survival in Stage III Non–Small-Cell Lung Cancer
Wang EH, Rutter CE, Corso CD, Decker RH, Wilson LD, Kim AW, Yu JB, Park HS. Patients Selected for Definitive Concurrent Chemoradiation at High-volume Facilities Achieve Improved Survival in Stage III Non–Small-Cell Lung Cancer. Journal Of Thoracic Oncology 2015, 10: 937-943. PMID: 25738221, DOI: 10.1097/jto.0000000000000519.Peer-Reviewed Original ResearchConceptsDefinitive concurrent chemoradiation therapyConcurrent chemoradiation therapyHigh-volume facilitiesNon-small cell lung cancerStage III NSCLC patientsCell lung cancerOverall survivalNSCLC patientsLung cancerStage III non-small cell lung cancerHigher Charlson-Deyo comorbidity scoresCharlson-Deyo comorbidity scoreNational Cancer Data BaseCox proportional hazards regressionFacility case volumeImproved overall survivalAdvanced nodal stageDefinitive concurrent chemoradiationKaplan-Meier analysisPopulation-based survivalMultivariable logistic regressionProportional hazards regressionRisk of deathIntensity-modulated radiotherapyAcademic affiliation